Before the opening bell on Tuesday, July 16, Domino’s Pizza (NYSE: DPZ) will mark the beginning of another earnings season by announcing its second quarter financial results. Helped by its massive store expansion strategy, the pizza company is expected to report about a 7% increase in revenues to $836.92 million.
Meanwhile, same-store sales in the US could likely be hurt by food delivery apps such as GrubHub (NYSE: GRUB) and Uber Eats. One of the USPs of Domino’s was its fast delivery of food orders to customers. With the arrival of these delivery companies, this is no longer a USP.
The Ann Arbor Charter Township, Michigan-based restaurant chain is hoping to beat this by opening stores in as many locations as possible, which, in turn, would cut down delivery times. At the end of the first quarter of 2019, the company had 1,148 more stores than it did a year ago.
During the first quarter, domestic same-store sales grew 3.9%, vs. 8.3% growth it reported in the prior-year quarter. The management is likely to talk in detail about its contingency plan to lift its same-store sales, in the face of severe competition from food delivery firms.
Revenues from supply chain and franchise are expected to see continued strength, with year-over-year growth projected at around 10% for both. Meanwhile, market observers are anticipating a modest decline in domestic company-owned stores.
Wall Street anticipates Q2 earnings of $2.02 per share, compared to $1.84 it reported during the year-over period, helped by its aggressive cost optimization measures.
DPZ shares have gained 14% in the year-to-date period. According to TipRanks, the stock has a 12-month average price target of $312.58, suggesting a 12.5% upside from the last close.
Pizza Hut-parent Yum Brands (NYSE: YUM) and Papa John’s are both slated to announce financial results early next month (NASDAQ: PZZA).
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
Comments
Comments are closed.